• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Once-a-month fitusiran reduces bleeding rates in patients with hemophilia A and B with inhibitors

byNeel MistryandTeddy Guo
May 16, 2023
in Chronic Disease, Hematology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Annualized bleeding rate was reduced by 91% in the fitusiran prophylaxis group compared to the bypassing agents on-demand group.

2. 5% of patients in the fitusiran group reported thromboembolic events; there were no deaths.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Hemophilia is marked by a deficiency in certain coagulation factors that make patients prone to bleeding. Prophylaxis is the standard of care in these patients but is often complicated by the need for frequent transfusions and loss of intravenous access. Fitusiran is a novel small interfering RNA that may regulate hemostasis through the inhibition of antithrombin synthesis, although its use in hemophilia patients is not well known. This randomized controlled trial aimed to compare the safety and efficacy of fitusiran in patients with hemophilia A and hemophilia B with inhibitors. The primary outcome was the mean annualized bleeding rate while key secondary outcomes included joint and spontaneous bleeding rate and mobility concerns. According to study results, patients in the fitusiran group reported significantly reduced bleeding events and greater hemostatic efficacy compared to the bypassing agents on-demand group. Although this study was well done, it included a small sample size with a 2:1 randomization in favor of the intervention group. Additionally, excluding patients with less than 60% antithrombin activity may reduce the generalizability of these results to other patients with hemophilia.

Click to read the study in The Lancet

Relevant Reading: Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A

RELATED REPORTS

AAV gene therapy shows durable benefit in hemophilia B

Hereditary erythrocytosis is associated with a fetal-like EPO isoform

Reduced-dose apixaban noninferior to full dose for cancer-associated thrombosis

In-depth [randomized-controlled trial]: Between Feb 14, 2018, and Jun 23, 2021, 85 patients were screened for eligibility across 26 sites in 12 countries. Included were male patients aged ≥ 12 years with hemophilia A or hemophilia B and ≥ 6 bleeding episodes in the past 6 months. Participants with lower than 60% antithrombin activity were excluded. The primary outcome of mean annualized bleeding was significantly lower in the fitusiran prophylaxis group (1.7, 95% confidence interval [CI] 1.0-2.7) compared to the bypassing agents on-demand group (18.1, 95% CI 10.6-30.8), denoting a 91% reduction in bleeding (p<0.0001). Substantially more patients in the fitusiran group (66%) had zero treated bleeds compared to the latter (5%). The majority of adverse events were mild-to-moderate with elevated liver enzymes in 32% and thromboembolic events in 5% of patients in the fitusiran group. There were no treatment-related fatalities. Findings from this study suggest that prophylaxis with fitusiran significantly reduces bleeding among hemophilia patients and may improve clinical outcomes.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bleedingfitusiranhematologyhemophiliahemophilia AHemophilia Bhemostasismajor bleeding
Previous Post

The Scan by 2 Minute Medicine®: Mammogram Recommendation Changes, COVID Called Off, Canadian Wildfires, and National Nurses Week

Next Post

High-dose corticosteroids increase morbidity and mortality among hypoxic COVID-19 patients

RelatedReports

Primary thromboembolism prophylaxis may be effective in advanced cancer
Hematology

AAV gene therapy shows durable benefit in hemophilia B

July 7, 2025
New genetic link in pulmonary arterial hypertension holds therapeutic promise
Chronic Disease

Hereditary erythrocytosis is associated with a fetal-like EPO isoform

June 2, 2025
Thrombophilia-associated stillbirth risk appears limited to factor V Leiden
Hematology

Reduced-dose apixaban noninferior to full dose for cancer-associated thrombosis

May 20, 2025
Quick Take: Hospital volume and outcomes for acute pulmonary embolism
Cardiology

Analysis of clinical outcomes utilizing ultrasound-assisted catheter-directed thrombolysis for pulmonary embolism

April 30, 2025
Next Post
Novel coronavirus identified from patients with pneumonia in Wuhan, China

High-dose corticosteroids increase morbidity and mortality among hypoxic COVID-19 patients

Female incontinence associated with physical activity

Wellness Check: Exercise

The 2 Minute Medicine Podcast Episode 15

The 2 Minute Medicine Podcast Episode 15

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
  • Mazdutide significantly reduces weight in adults with overweight or obesity
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.